image credit- shutterstock
Jaoan-based Shimadzu has announced the merger of its reagent company, Alsachim SAS (France, abbreviated as ALC), as the absorbing company with Biomaneo SAS (France, abbreviated as BMO), as the absorbed company and change its name to Shimadzu Chemistry and Diagnostics SAS (France, abbreviated as SCHD).
ALC develops and manufactures reagent kits for liquid chromatography-mass spectrometry (LC-MS) and stable isotope reagents , while BMO develops and manufactures clinical software and reagent kits for matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-MS).
Both companies possess technologies that are essential for the growth of the group's clinical LC-MS business and will create synergies and strengthen governance through management integration.
SCHD, the new company, will consolidate the businesses of ALC and BMO into a single entity to enhance development functions that meet customer needs. In addition, SCHD will accelerate the global expansion of comprehensive clinical solutions, including LC-MS, reagent kits, and software, through collaboration with Shimadzu headquarters. Shimadzu will continue to provide comprehensive clinical solutions that combine SCHD products with its own LC-MS and MALDI-MS.
